This raises the question whether general PTP profiles are influenced by characteristic genetic alterations associated with lower grade glioma (frequently IDH-mutant) or glioblastoma (e.g. EGFR amplification; PTEN deletion) or rather reflect the tumor pathogenesis, including cell of origin. The gene discussed is IDH1; the disease is central nervous system cancer.